You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 5, 2024

CLINICAL TRIALS PROFILE FOR DEXACEN-4

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for DEXACEN-4

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03031730 ↗	Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma	Recruiting	National Cancer Institute (NCI)	Phase 1	2017-10-27	This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of multiple myeloma. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving MDM2 Inhibitor KRT-232, lenalidomide, carfilzomib, and dexamethasone together may work better in treating patients with multiple myeloma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for DEXACEN-4

Condition Name

Chart
Table

Condition Name for DEXACEN-4
Intervention	Trials
Hypercalcemia	1
Plasmacytoma	1
Recurrent Plasma Cell Myeloma	1
Refractory Plasma Cell Myeloma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for DEXACEN-4
Intervention	Trials
Multiple Myeloma	1
Hypercalcemia	1
Plasmacytoma	1
Neoplasms, Plasma Cell	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for DEXACEN-4

Trials by Country

Map
Table

Trials by Country for DEXACEN-4
Location	Trials
United States	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for DEXACEN-4
Location	Trials
Utah	1
Texas	1
Colorado	1
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for DEXACEN-4

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for DEXACEN-4
Clinical Trial Phase	Trials
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for DEXACEN-4
Clinical Trial Phase	Trials
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DEXACEN-4

Sponsor Name

Chart
Table

Sponsor Name for DEXACEN-4
Sponsor	Trials
National Cancer Institute (NCI)	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for DEXACEN-4
Sponsor	Trials
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.